Form 4: Rocket Pharmaceuticals CEO Gaurav Shah Reports Stock Transactions
SEC Form 4 Filing
CEO Gaurav Shah of Rocket Pharmaceuticals reports acquisition and disposal of common stock and restricted stock units (RSUs).
Summary
- Gaurav Shah, CEO of Rocket Pharmaceuticals, filed a Form 4 detailing changes in beneficial ownership.
- On May 14, 2024, Shah acquired 7,979 and 9,683 shares of common stock at $0 related to RSU vesting.
- He also reports holdings of 207,897 shares indirectly through his spouse and 198,341 shares indirectly through the Gaurav D. Shah Irrevocable Trust.
- On May 16, 2024, Shah disposed of 9,790 shares of common stock at $23.35.
- The transactions also involve the vesting and settlement of Restricted Stock Units (RSUs).
- The filing updates the reporting person's history to include RSUs on Table I.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing detailing stock transactions by the CEO. It doesn't inherently convey positive or negative sentiment.
Industry Context
Form 4 filings are standard practice for company insiders to report transactions in their company's stock, ensuring transparency and compliance with SEC regulations.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in the CEO's holdings.
Key Dates
| Date | Description |
|---|---|
| 02/14/2022 | Initial grant date of some Restricted Stock Units (RSUs). |
| 02/14/2023 | Initial grant date of some Restricted Stock Units (RSUs). |
| 05/14/2024 | Date of common stock acquisition due to RSU vesting. |
| 05/16/2024 | Date of common stock disposal. |
| 05/20/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.